

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Last Update: Nov 20, 2024

An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis

ClinicalTrials.gov Identifier:

[NCT03650114](#)

Novartis Reference Number: COMB157G2399

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study.

Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).

COVID-19 sub-study:

The purpose of this research sub-study is to explore the immune response following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination in a subset of subjects on long-term ofatumumab 20 mg sc. Note: Novartis is not supplying the SARS-CoV-2 vaccine.

Condition

Relapsing Multiple Sclerosis

Phase

Phase3

Overall Status

Recruiting

Number of Participants

2060

Start Date

<!-- THEME DEBUG -->

<!-- THEME HOOK: 'printable_pdf_footer' -->

Dec 28, 2018

GIN OUTPUT from 'modules/contrib/printable/modules/printable_pdf/templates/printable-footer.html.t

Completion Date

1/9

Sep 30, 2028

Gender

ND OUTPUT from 'modules/contrib/printable/modules/printable_pdf/templates/printable-footer.html.tw

All

Age(s)

18 Years - 100 Years (Adult, Older Adult)

<!-- THEME DEBUG -->

<!-- THEME HOOK: 'printable_pdf_header' -->

OM TEMPLATE OUTPUT from 'themes/custom/polaris/templates/print/printable-header.html.twig' -->

Interventions

OM TEMPLATE OUTPUT from 'themes/custom/polaris/templates/print/printable-header.html.twig' -->

Biological

13-valent pneumococcal conjugate vaccine (13-PCV)

0.5mL Vial/Syringe

Biological

23-valent pneumococcal polysaccharide vaccine (23-PPV)

0.5mL Vial/Syringe

Biological

Keyhole limpet hemocyanin (KLH) neo-antigen

1mg Vial

Biological

Ofatumumab

subcutaneous injection of 20 mg ofatumumab every 4 weeks

Biological

Seasonal Quadrivalent influenza vaccine

Seasonal 2020-2021 0.5mL Vial/Syringe (trivalent may be used where quadrivalent is not available)

Biological

Tetanus toxoid (TT) containing vaccine (Td, Tdap)

0.5mL Vial/Syringe Containing 5 limit of flocculation (LF) tetanus toxoid

Eligibility Criteria

Inclusion Criteria:

1. Must have completed a selected Novartis MS study which dosed ofatumumab 20 mg sc every 4 weeks
2. Written informed consent

Exclusion Criteria:

- * Emergence of any clinically significant condition/disease during the previous ofatumumab study in which study participation might result in safety risk for the subject

GIN OUTPUT from 'modules/contrib/printable/modules/printable_pdf/templates/printable-footer.html.t

- * Subjects with active systemic bacterial, viral or fungal infections, or chronic infection (e.g. AIDS)

- * Subjects taking medications prohibited by the protocol

ND OUTPUT from 'modules/contrib/printable/modules/printable_pdf/templates/printable-footer.html.tw

Vaccination sub-study:

<!-- THEME DEBUG -->

Inclusion criteria

<!-- THEME HOOK: 'printable_pdf_header' -->

OM TEMPLATE OUTPUT from 'themes/custom/polaris/templates/print/printable-header.html.twig' -->

1. Informed consent

2. Actively enrolled in the COMB157G2399 Study

OM TEMPLATE OUTPUT from 'themes/custom/polaris/templates/print/printable-header.html.twig' -->

3. 12 weeks of continuous treatment within the COMB157G2399 Study

4. prior vaccination history as per protocol-defined

Exclusion criteria

* known hypersensitivity or history of systemic allergic, neurologic or other reactions to vaccines

* allergies to egg or shellfish

* any safety findings including low IgG/IgM requiring ofatumumab interruption within 12 weeks prior to vaccination sub-study start

* any major episode of infection requiring hospitalization or treatment with intravenous antibiotics within 2 weeks of the first vaccination sub-study visit

Other protocol-defined inclusion/exclusion criteria may apply

United States

The Neuromedical Center

Recruiting

Baton Rouge, Louisiana, 70810, United States

Danielle Bryant

Phone: [608-848-8900](tel:608-848-8900)

Email: dbryant@delricht.com

Jon Olson

University of Tennessee Medical Center

Recruiting

Knoxville, Tennessee, 37920, United States

Randall Trudell

Patricia Pryor

Phone: [865-305-9100](tel:865-305-9100)

Email: patricia.pryor@amrllc.com

<!-- THEME DEBUG -->

<!-- THEME HOOK: 'printable_pdf_footer' -->

ND OUTPUT from 'modules/contrib/printable/modules/printable_pdf/templates/printable-footer.html.twig' -->

University of Kansas Hospital

3/9

Recruiting

ND OUTPUT from 'modules/contrib/printable/modules/printable_pdf/templates/printable-footer.html.twig' -->
Kansas City, Kansas, 66160, United States

Lisa Schmidt

Phone: [913-588-0614](tel:913-588-0614)

Email: Lisa.Schmidt@kumc.edu

Sharon Lynn

Billings Clinic

Recruiting

Billings, Montana, 59101, United States

Sarah Hall

Phone: [406-435-7459](tel:406-435-7459)

Email: shall6@billingsclinic.org

Sara Qureshi

Evergreen Health Multiple Sclerosis Center

Recruiting

Kirkland, Washington, 98034, United States

Amenah Al Khafaji

Phone: [425-899-0555](tel:425-899-0555)

Email: AAAlKhafaji@evergreenhealthcare.org

Theodore Brown

Neurology Offices of South Florida PLLC

Recruiting

Delray Beach, Florida, 33445, United States

Phone: [561-482-1027](tel:561-482-1027)

Brian Costell

Neurology and Sleep Center

Recruiting

Lubbock, Texas, 79410, United States

GIN OUTPUT from 'modules/contrib/printable/modules/printable_pdf/templates/printable-footer.html.t

Bhupesh Dihenia

ND OUTPUT from 'modules/contrib/printable/modules/printable_pdf/templates/printable-footer.html.tw

Phone: [806-722-3500](tel:806-722-3500)

Email: zenaida.hernandez806@outlook.com

<!-- THEME DEBUG -->

<!-- THEME HOOK: 'printable_pdf_header' -->

ON TEMPLATE OUTPUT from 'themes/custom/polaris/templates/print/printable-header.html.twig' -->

ON TEMPLATE OUTPUT from 'themes/custom/polaris/templates/print/printable-header.html.twig' -->

Birmingham,Alabama,35233-0271,United States

Jennifer Mahaffey

Phone: [205-502-9967](tel:205-502-9967)

Email: jdmahaffey@uabmc.edu

Khurram Bashir

Cleveland Clinic Foundation

Recruiting

Cleveland,Ohio,44195,United States

Jeffrey Cohen

Tammy Skaramagas

Phone: [216-445-2572](tel:216-445-2572)

Email: skaramt1@ccf.org

Wayne State University Multiple Sclerosis Clinic

Recruiting

Detroit,Michigan,48201,United States

Carla Santiago

Phone: [313-745-4220](tel:313-745-4220)

Email: csantiago@med.wayne.edu

Jacob Rube

College Park Family Care Center

Recruiting

Overland Park,Kansas,66210,United States

<!-- THEME HOOK: 'printable_pdf_footer' -->

GIN OUTPUT from 'modules/contrib/printable/modules/printable_pdf/templates/printable-footer.html.t

Jeffrey Kaplan

Kristen Giese

ND OUTPUT from 'modules/contrib/printable/modules/printable_pdf/templates/printable-footer.html.tw

Phone: [913-469-9887](tel:913-469-9887)

Email: Kristen.giese@hcahealthcare.com

<!-- THEME DEBUG -->

<!-- THEME HOOK: 'printable_pdf_header' -->

OM-TEMPLATE OUTPUT from 'themes/custom/polaris/templates/print/printable-header.html.twig' -->

OM-TEMPLATE OUTPUT from 'themes/custom/polaris/templates/print/printable-header.html.twig' -->

Chicago,Illinois,60612,United States

Christian Holt

Phone: [312-942-8011](tel:312-942-8011)

Email: Christian_Holt@rush.edu

Thomas Shoemaker

Hope Neurology

Recruiting

Knoxville,Tennessee,37922,United States

Sarah Waters

Phone: [865-218-6222](tel:865-218-6222)

Email: swaters@hopeneuro.com

Sibyl Wray

North Central Neurology Associates PC

Recruiting

Cullman,Alabama,35058,United States

Christopher LaGanke

Magan Bender

Phone: [256-739-1210](tel:256-739-1210)

Email: mbender@prn-inc.net

Lonestar Neurology of San Antonio

Recruiting

San Antonio,Texas,78258,United States <!-- THEME DEBUG -->

<!-- THEME HOOK: 'printable_pdf_footer' -->

GIN-OUTPUT from 'modules/contrib/printable/modules/printable_pdf/templates/printable-footer.html.t

Ann Bass

Virginia Vazquez

ND OUTPUT from 'modules/contrib/printable/modules/printable_pdf/templates/printable-footer.html.tw

Phone: [+1 210 490 0016#23](tel:+12104900016#23)

Email: Virginia@lonestarneurology.net

<!-- THEME DEBUG -->

<!-- THEME HOOK: 'printable_pdf_header' -->

TM-TEMPLATE OUTPUT from 'themes/custom/polaris/templates/print/printable-header.html.twig' -->

TM-TEMPLATE OUTPUT from 'themes/custom/polaris/templates/print/printable-header.html.twig' -->

Cordova, Tennessee, 38018, United States

Phone: [901-866-9252](tel:901-866-9252)

Kendrick K Henderson

Henry Ford Hospital

Recruiting

Detroit, Michigan, 48202 2689, United States

Phone: [313-556-8186](tel:313-556-8186)

Mirela Cerghet

Neuro Medical Clinic of Cenla LLC

Recruiting

Alexandria, Louisiana, 71301, United States

Ariel Antezana-Antezana

Mary Rabalais

Phone: [318-443-0490](tel:318-443-0490)

Email: mary.rabalais@intrafusion.com

Josephson Wallack Munshower Neurology P.C

Recruiting

Indianapolis, Indiana, 46256, United States

Phone: [+1 \(317\) 537-6060](tel:+1(317)537-6060)

Craig Edward Herrman

Jem Research Institute

<!-- THEME DEBUG -->

<!-- THEME HOOK: 'printable_pdf_footer' -->

Recruiting

GIN OUTPUT from 'modules/contrib/printable/modules/printable_pdf/templates/printable-footer.html.t

Atlantis, Florida, 33462-6608, United States

7/9

ND OUTPUT from 'modules/contrib/printable/modules/printable_pdf/templates/printable-footer.html.tw

Phone: [+1 561 966 2900002](tel:+1561966-2900002)

Texas Institute for Neurological Disorders

OM TEMPLATE OUTPUT from 'themes/custom/polaris/templates/print/printable-header.html.twig' -->
Recruiting

OM TEMPLATE OUTPUT from 'themes/custom/polaris/templates/print/printable-header.html.twig' -->
Sherman,Texas,75092,United States

Phone: +1 903 893 5141#4334

Bharathy E. Sundaram

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: +41613241111

Email:

Novartis Pharmaceuticals

Phone: 1-888-669-6682

Email: Novartis.email@novartis.com

Source URL: *https://dev.arctic.novartis.com/clinicaltrials/study/nct03650114*

List of links present in page

1. <https://clinicaltrials.gov/ct2/show/NCT03650114>
2. [#trial-eligibility](#)
3. <tel:608-848-8900>
4. <mailto:dbryant@delricht.com>
5. <tel:865-305-9100>
6. <mailto:patricia.pryor@amrllc.com>
7. <tel:913-588-0614>
8. <mailto:lschmidt@kumc.edu>
9. <tel:406-435-7459>
10. <mailto:shall6@billingsclinic.org>
11. <tel:425-899-0555>
12. <mailto:AAAIKhafaji@evergreenhealthcare.org>
13. <tel:561-482-1027>
14. <tel:806-722-3500>
15. <mailto:zenaida.hernandez806@outlook.com>
16. <tel:205-502-9967>
17. <mailto:jdmahaffey@uabmc.edu>
18. <tel:216-445-2572>
19. <mailto:skaramt1@ccf.org>
20. <tel:313-745-4220>
21. <mailto:csantiago@med.wayne.edu>
22. <tel:913-469-9887>


```

23. mailto:Kristen.giese@hcahealthcare.com
24. tel:312-942-8011
25. mailto:Christian_Holt@rush.edu
26. tel:965-218-6022
27. mailto:swaters@hopeneuro.com
28. tel:256-739-1210
29. mailto:mbender@prn-inc.net
30. tel:+1 210 490 0016#23
31. mailto:Virginia@lonestarneurology.net
32. tel:901-866-9252
33. tel:313-556-8186
34. tel:318-443-0490
35. mailto:mary.rabalais@intrafusion.com
36. tel:+1 (317) 537-6060
37. tel:+1 561 968 2933 302
38. tel:+1 903 893 5141#4334
39. tel:+41613241111
40. mailto:
41. tel:1-888-669-6682
42. mailto:Novartis.email@novartis.com

```